Lundbeck CEO Ulf Wiinberg Steps Down After Breaching Code Of Conduct
This article was originally published in The Pink Sheet Daily
Candidates for the post in the Danish biotech are likely to have a commercial background, as Wiinberg-inspired strategy of geographic expansion and a growing a pipeline of CNS products continues to bear fruit.
You may also be interested in...
One of the first priorities for Lundbeck’s new chief executive will be supporting new product launches worldwide to boost the Danish company’s geographic and product diversification.
Sanofi announced that Christopher Viehbacher has resigned as CEO after its board voted unanimously to remove him. The drama comes amid serious worries over the group’s cash cow medicine, Lantus.
Danish pharma increases investment in new product launches as it prepares for loss of patent protection on its lead product, escitalopram.